JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

Search

Incyte Corp

Deschisă

SectorSănătate

89.78 -1.01

Rezumat

Modificarea prețului

24h

Curent

Minim

87.87

Maxim

94.32

Indicatori cheie

By Trading Economics

Venit

247M

405M

Vânzări

163M

1.2B

P/E

Medie Sector

20.714

37.461

Marjă de profit

33.319

Angajați

2,617

EBITDA

324M

582M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

-5.53% downside

Statistici piață

By TradingEconomics

Capitalizare de piață

3.5B

17B

Deschiderea anterioară

90.79

Închiderea anterioară

89.78

Sentimentul știrilor

By Acuity

26%

74%

57 / 373 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Incyte Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

28 oct. 2025, 23:50 UTC

Acțiuni populare

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 oct. 2025, 23:25 UTC

Câștiguri

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 oct. 2025, 23:18 UTC

Câștiguri

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 oct. 2025, 22:20 UTC

Câștiguri

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 oct. 2025, 22:13 UTC

Câștiguri

Wal-Mart de Mexico Net Profit Falls in 3Q

28 oct. 2025, 21:38 UTC

Câștiguri

Correction to Visa Sales Jump Article

28 oct. 2025, 21:17 UTC

Câștiguri

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 oct. 2025, 21:07 UTC

Câștiguri

Visa Sales Jump as Consumers Keep Spending -- Update

28 oct. 2025, 21:02 UTC

Câștiguri

Mondelez Tempers Outlook as Costs Rise

28 oct. 2025, 23:51 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 oct. 2025, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 oct. 2025, 23:02 UTC

Câștiguri

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 oct. 2025, 23:01 UTC

Câștiguri

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 oct. 2025, 22:46 UTC

Câștiguri

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 oct. 2025, 22:45 UTC

Câștiguri

SK Hynix 3Q Net KRW12.6T >000660.SE

28 oct. 2025, 22:44 UTC

Câștiguri

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 oct. 2025, 22:43 UTC

Câștiguri

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 oct. 2025, 22:42 UTC

Câștiguri

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 oct. 2025, 22:40 UTC

Câștiguri

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 oct. 2025, 22:40 UTC

Câștiguri

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 oct. 2025, 22:22 UTC

Câștiguri

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 oct. 2025, 22:22 UTC

Câștiguri

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 oct. 2025, 22:22 UTC

Câștiguri

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 oct. 2025, 22:20 UTC

Câștiguri

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 oct. 2025, 22:02 UTC

Câștiguri

Review & Preview: Earnings Extravaganza -- Barrons.com

28 oct. 2025, 21:42 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

28 oct. 2025, 21:42 UTC

Market Talk
Câștiguri

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 oct. 2025, 21:20 UTC

Câștiguri

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 oct. 2025, 21:19 UTC

Câștiguri

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 oct. 2025, 21:18 UTC

Câștiguri

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Comparație

Modificare preț

Incyte Corp Așteptări

Obiectiv de preț

By TipRanks

-5.53% jos

Prognoză pe 12 luni

Medie 87.93 USD  -5.53%

Maxim 115 USD

Minim 60 USD

În baza a 18 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIncyte Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

18 ratings

7

Cumpărare

10

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

59.52 / 62.66Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

57 / 373 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
help-icon Live chat